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Methylation age acceleration does not
predict mortality in schizophrenia
Kaarina Kowalec 1,2, Eilis Hannon 3, Georgina Mansell3, Joe Burrage3, Anil P. S. Ori4, Roel A. Ophoff4,
Jonathan Mill 3 and Patrick F. Sullivan1,5
Abstract
Schizophrenia (SCZ) is associated with high mortality. DNA methylation levels vary over the life course, and pre-
selected combinations of methylation array probes can be used to estimate “methylation age” (mAge). mAge
correlates highly with chronological age but when it differs, termed mAge acceleration, it has been previously
associated with all-cause mortality. We tested the association between mAge acceleration and mortality in SCZ and
controls. We selected 190 SCZ cases and 190 controls from the Sweden Schizophrenia Study. Cases were identified
from the Swedish Hospital Discharge Register with ≥5 specialist treatment contacts and ≥5 antipsychotic prescriptions.
Controls had no psychotic disorder or antipsychotics. Subjects were selected if they had died or survived during
follow-up (2:1 oversampling). Extracted DNA was assayed on the Illumina MethylationEPIC array. mAge was regressed
on age at sampling to obtain mAge acceleration. Using Cox proportional hazards regression, the association between
mAge acceleration and mortality was tested. After quality control, the following were available: n= 126 SCZ died, 63
SCZ alive, 127 controls died, 62 controls alive. In the primary analyses, we did not find a significant association between
mAge acceleration and SCZ mortality (adjusted p > 0.005). Sensitivity analyses excluding SCZ cases with pre-existing
cancer demonstrated a significant association between the Hannum mAge acceleration and mortality (hazard ratio=
1.13, 95% confidence interval= 1.04–1.22, p= 0.005). Per our pre-specified criteria, we did not confirm our primary
hypothesis that mAge acceleration would predict subsequent mortality in people with SCZ, but we cannot rule out
smaller effects or effects in patient subsets.
Introduction
Schizophrenia (SCZ) is associated with significantly
higher mortality and 12–15 years decreased life expec-
tancy compared to healthy individuals1. The causes of
increased mortality in SCZ may include internal (i.e.,
genetic risk) and external factors, such as adverse health
behaviors (i.e., smoking) or the under-diagnosis and
under-treatment of common causes of mortality, includ-
ing cancer and ischemic heart disease1. Another possibi-
lity for increased mortality relates to the hypothesis of
accelerated aging, that is, factors associated with the dis-
order accelerates changes in biological status. This has
been investigated previously in major depressive disorder,
using a DNA methylation-based method2. DNA methy-
lation in nucleated blood cells varies over the course of
life3–5, with levels across multiple sites used to derive an
estimate of “DNA methylation age” (mAge), which cor-
relates highly with chronological age6–8. The deviation
between mAge and chronological age (i.e., accelerated
mAge) has been identified as a potential risk factor for
age-related diseases and all-cause mortality in non-
psychiatric studies6–10.
Individuals with major depressive disorder have exhib-
ited mAge acceleration in whole blood and post-mortem
brain tissues suggesting accelerated aging2. Studies
investigating the accelerated aging hypothesis in post-
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traumatic stress disorder and mAge have yielded mixed
results. A meta-analysis of 2,186 individuals found no
association between advanced mAge and lifetime trauma
exposure or post-traumatic stress disorder11 and accel-
erated mAge was marginally associated with childhood
trauma (p= 0.028) and lifetime post-traumatic stress
disorder severity (p= 0.016)11. In SCZ, accelerated aging
according to mAge has been investigated, however find-
ings using Horvath mAge estimates in either brain tis-
sue12–15 or blood samples16 have been insignificant. These
previous studies of mAge acceleration and SCZ did not
focus specifically on mortality and were also limited to the
use of a single mAge estimator (Horvath).
mAge can be estimated from Illumina methylation
arrays using different algorithms, principally the Han-
num6, Horvath8, and Levine9 estimators. The Hannum
estimator was developed using 71 CpG sites from adult
whole blood samples6. This contrasts with the Horvath
estimator, which was developed using 353 CpG sites from
multiple tissues from children and adults8. The most
recent is the Levine mAge estimator, which incorporates
clinical measures to capture phenotypic differences asso-
ciated with health span and lifespan along with 513 CpG
probes in adults9. The Horvath mAge calculator has been
used frequently in scientific studies due to ease of calcu-
lation and multi-tissue applicability; however, many stu-
dies, including a recent investigation into the association
between mAge acceleration and mortality, used both
Hannum and Horvath methods and found high agree-
ment between the estimators7.
To the best of our knowledge, a specific investigation
into whether accelerated mAge is associated with sub-
sequent mortality in SCZ has not been done and may help
inform or predict risk of mortality in individuals with
SCZ. Here, using a sample from Sweden17, we tested the
association between mAge acceleration and mortality in
individuals with SCZ and controls. Critically, this was an
older cohort as the mean age at sampling was in the mid-
50 s and followed for a median of 6 years. Based on the
literature7,10,18, we hypothesized that accelerated mAge
would predict subsequent death in middle-aged indivi-
duals with SCZ, when compared to SCZ who were alive
and compared to controls.
Methods and materials
Study design and study population
Our study is a case-control sample of participants in the
Sweden Schizophrenia Study (S3)17. S3 is a population-
based cohort of individuals born in Sweden including
4,936 SCZ cases and 6,321 healthy controls recruited
between 2004–2010. SCZ cases were identified from the
Swedish Hospital Discharge Register19,20 with ≥2 hospi-
talizations with a discharge diagnosis of SCZ or schi-
zoaffective disorder (SAD)21. This operational definition
of SCZ was validated in clinical, epidemiological, genetic
epidemiological, and genetic studies17. More generally,
the Hospital Discharge Register has high agreement with
medical19,20 and psychiatric diagnoses22. Controls were
also selected through Swedish Registers and were group-
matched by age, sex and county of residence and had no
lifetime diagnoses of SCZ, SAD, or bipolar disorder or
antipsychotic prescriptions. In S3, a significantly higher
proportion of those with SCZ died (n= 766, 15.5%) dur-
ing follow up compared to controls who died (n= 197,
3.1%, p= 2 × 10−120).
We studied four groups: (A) SCZ who died at follow up,
(B) SCZ still alive at follow up, (C) controls who died at
follow up, and (D) controls still alive at follow up (Table
1). Possessing both alive and dead cases and controls is
ideal as it will assist with investigating a potential ‘dose-
response’ relationship of mAge acceleration and death18.
We obtained the data for creating these groups from
Swedish national registers. Redeemed antipsychotic drug
prescriptions (Anatomical Therapeutic Chemical [ATC]
Classification codes beginning only with N05A) were
collected from the Sweden National Prescribed Drug
Register23. Mortality was determined using the Swedish
Cause of Death Register, which contains official causes of
Table 1 Subject groups for analysis
SCZ-died SCZ-alive Control-died Control-alive
Criteria SCZ with ≥5 specialist treatment contacts for SCZ or SAD & ≥5
antipsychotic prescriptions
No lifetime SCZ, SAD, or bipolar disorder or antipsychotic
prescriptions
N 127 63 127 63
Age at sampling 45–65 years 45–65 years 45–85 years 45–65 years
Follow up Died ≥1 year after sampling Alive ≥3 years after
sampling
Died ≥1 year after sampling Alive ≥3 years after
sampling
Exclusion Removed deaths by suicide,
accident, or violence
None Removed deaths by suicide,
accident, or violence
None
SCZ schizophrenia, SAD schizoaffective disorder
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death using International Classification of Diseases (ICD)-
10 codes (all deaths occurred after 1997)24. We over-
sampled those who died in a 2:1 ratio as we were parti-
cularly interested in the association between mortality and
mAge acceleration. Subjects were selected if they were
between 45–65 years old at the time of sampling (there
were insufficient numbers of controls who died, so we
increased the upper age boundary for this group to 85
years). We excluded subjects, prior to selecting the sam-
ples for methylation arrays, who died by external, un-
natural causes of death (e.g., accident or violence) as these
causes of death may have been more stochastic and less
connected to mAge acceleration. We reasoned that any
advantages of including these subjects (i.e., these deaths
might be related to SCZ indirectly leading to dangerous
behavior and aggressiveness) were outweighed by the
greater probability that un-natural deaths were unrelated
to mAge acceleration.
All subjects were 18 years of age or older and provided
written informed consent. Ethical permission was
obtained from the Karolinska Institutet Ethical Review
Committee in Stockholm, Sweden.
mAge estimation
Blood samples were drawn at enrolment. 500 ng of
DNA from each sample was treated with sodium bisulfite,
using the EZ-96 DNA methylation-Gold kit (Zymo
Research, CA, USA). DNA methylation was quantified
using the Illumina Infinium HumanMethylationEPIC
BeadChip (866,562 methylation sites across the genome)
(Illumina Inc, CA, USA) and run on an Illumina iScan
System (Illumina, CA, USA) using the manufacturers’
standard protocol25. In addition, a fully methylated con-
trol (CpG Methylated HeLa Genomic DNA; New England
BioLabs, MA, USA) was included in a random position on
each plate to facilitate sample tracking, resolve experi-
mental inconsistencies, and confirm data quality. To
reduce chip effects, we block randomized samples by
group, age at sampling, and sex in groups of eight to each
methylation chip using the R package OSAT26. The out-
put of this array is the ratio of methylated:unmethylated
alleles to quantify a β-value ranging from 0 (completely
unmethylated) to 1 (completely methylated). Subjects
were removed if methylated and unmethylated signal
intensities < 2000, bisulfite conversion < 80%, sex mis-
match, and/or if >1% of probes had detection p-value <
0.05. Methylation probes were removed if >1% of samples
have detection p-value < 0.05 or if >5% of samples had a
bead count < 3. The methylation data were then quantile-
normalized using the dasen function from the wateR-
melon R package27. As methylation data can be subject to
measurement variation, we also normalized the methyla-
tion data using the ENmix R package28, which employs a
mixture of exponential and truncated normal
distributions to model background noise. Two samples
whose predicted sex did not match their reported sex
were excluded during quality control (1 SCZ died, 1
control alive), leaving a total of 378 samples and 809,996
methylation probes for analysis.
DNA methylation is robustly associated with tobacco
smoking29. A per-individual smoking score (continuous
measure) was generated based on DNA methylation sites
known to be associated with smoking30. Using this method,
current smokers of European ancestry have been identified
with 100% sensitivity and 97% specificity30. To account for
methylation differences between cell types, we estimated
the cell-type composition of the blood samples using the
function estimateCellCounts (minfi R package)31.
Statistical analyses
mAge was computed using three different algorithms:
Hannum6 based on 71 methylation probes, Horvath8
using 353 probes, and Levine9 using 513 probes. The
residuals resulting from a linear regression of mAge on
age at sampling were used as the measure of mAge
acceleration for each mAge estimator. A positive value
indicates that the blood sample of the individual is older
than that of their chronological age. Horvath mAge was
calculated using the DNAmAge software (http://labs.
genetics.ucla.edu/horvath/dnamage), which includes the
use of an additional normalization step as part of its
procedures. Hannum and Levine mAge were estimated
using the coefficients listed by Hannum et al.6 and Levine
et al9.
Cox proportional hazards regression analyses (R
packages: survival, My.stepwise) were performed to
compare the mAge acceleration (separately for the three
mAge estimators) between: SCZ-died vs. SCZ alive; SCZ-
died vs. controls-died; and SCZ-died vs. controls alive.
Hazard ratios and corresponding 95% confidence intervals
were reported. Hazard ratios were adjusted for known
mortality risk factors (sex, age, smoking score, and white
blood cell composition) and for covariates known to affect
methylation (smoking score, array batch, and white blood
cell composition). We examined the Schoenfeld residuals
to test the proportional hazards assumption and the
hazards for mortality were proportional over time (p=
0.65). As a complementary analysis, we computed the
least square means (emmeans R package) in two linear
models: mAge (i.e., predicted mAge) and mAge accel-
eration (i.e., mAge residuals). These linear models inclu-
ded case/control status, died/alive, and their interaction
term along with the following covariates: sex, methylation
batch, white blood cell counts, and smoking score. The
mAge least square mean was additionally adjusted for age
at sampling.
We performed sensitivity analyses. First, to assess the
influence of acute illness on mAge acceleration, we
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removed all deaths that occurred < 2 years of sampling.
Second, we removed all individuals who were >65 years at
the time of sampling from the control-died group, given
the other subject groups were limited to ≤ 65 years. Third,
we removed all individuals with any previous inpatient or
outpatient contacts for a serious cancer (ICD codes for
serious cancers listed in Supplementary Table S1), given
the strong evidence for epigenetic changes in cancer32.
Lastly, we removed all individuals with any previous
contacts for a serious cancer and were >65 years at the
time of sampling. For these sensitivity analyses, we per-
formed a Cox proportional hazards regression analysis to
compare findings with the results from the main analysis.
All analyses were performed using R (version 3.3.3) and
R-Studio (version 1.0.143). We chose to adopt a more
stringent p-value level (p ≤ 0.005) to indicate statistical
significance33 and reduce the likelihood of a false positive
finding.
Results
Following quality control, the following groups were
available for analysis of mAge acceleration and mortality:
SCZ (ndied= 126, nalive= 63) and controls (ndied= 127,
nalive= 62) (Table 2). The median ages at sampling were
as expected across the four groups due to study design. As
noted in the literature1 and due to our study design, SCZ
cases had an earlier age at death, compared to controls
(median= 62.3 y vs. 71.2 y). Subjects who died had
approximately four years of follow-up time, compared to
5–6 years of follow up for those alive. Individuals with
SCZ had a similar number of inpatient and outpatient
hospitalizations between those who died compared to
alive, although those SCZ cases who were alive had a
higher number of antipsychotic prescriptions. The causes
of death between SCZ and controls were compared
(Supplementary Table S2), and as expected majority of
deaths in both groups occurred from cardiovascular dis-
ease and cancer1. SCZ subjects who died had a higher
median smoking score than the three other subject groups
(Table 2), in addition to a higher proportion of SCZ died
from respiratory diseases than controls. Therefore,
smoking score was an important covariate to consider in
the mAge acceleration analyses.
Methylation age acceleration and mortality
There were high correlations between age at sampling
and mAge for all three estimators (range for all samples
by estimator= 0.79–0.85, Supplementary Figure S1; range
Table 2 Descriptive statistics for the four groups for analysis
SCZ-died SCZ-alive Control-died Control-alive
N 126 63 127 62
Males, N (%) 76 (60.3) 38 (60.3) 71 (55.9) 40 (63.5)
Age at sampling, years 58 (53, 61) 56 (51, 60) 68 (61, 74) 57.5 (51, 61)
Age at death, years 62.3 (56.3, 65) N/A 71.2 (65.4, 78.4) N/A
Follow-up timea 3.95 (2.9, 5.5) 6(5, 6) 4.1 (2.8, 5.4) 5(5, 6)
Inpatient hospitalizationsb 13.5 (7.3, 24) 13 (7, 25.5) 0 0
Outpatient hospitalizationsb 9.5 (5, 16.8) 12(5, 19) 0 0
Antipsychotic prescriptions 140 (40.5, 247) 205 (90.5, 341) 0 0
Smoking score 6.2 (1.1, 9.6) 2.3 (−1.8, 7.1) −0.74 (−3.5, 3.4) −2.3 (−4.6, 0.2)
Hannum
mAge 53.7 (49.8, 56.7) 51.2 (48.4, 56.1) 60.7 (55.3, 65.9) 51.7 (49.1, 56.7)
mAge acceleration −0.17 (−2.5, 2.1) −0.40 (−2.3, 1.1) 0.04 (−2.2, 2.2) 0.20 (−2.8, 2.5)
Horvath
mAge 57.1 (52.6, 61.5) 55.2 (51.9, 58.6) 64.6 (58.5, 69.9) 57.2 (53.4, 60.8)
mAge acceleration 0.31 (−3.2, 2.9) −0.27 (−2.9, 1.5) −0.35 (−2.8, 2.5) 0.29 (−1.9, 2.7)
Levine
mAge 50.6 (45.9, 55.4) 47.8 (43.7, 53.3) 58.9 (52.4, 64.9) 48.2 (43.2, 52.4)
mAge acceleration 0.72 (−2.6, 3.6) −0.88 (−3.4, 2.5) 0.04 (−3.5, 3.5) −1.5 (−4.5, 3.1)
For continuous variables, the median and interquartile range are reported; for categorical variables, the number of individuals and percent are reported. For the
methylation age (mAge), the value is reported in years aFor those who died, time between sampling and death; for alive, this is time between sampling and last
follow-up bHospitalizations with discharge diagnoses of SCZ or schizoaffective disorder. N/A not applicable
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by sample for Hannum estimator= 0.73–0.82, Fig. 1).
Furthermore, there was significant overlap of the inter-
quartile ranges for the mAge acceleration for all subject
groups (Table 2). Choice of normalization method
(quantile-normalization using the dasen function versus
background correction using the ENmix package) for the
methylation data did not differ and was highly correlated
for each of the three mAge estimators (Horvath mAge: r
= 0.99, Hannum mAge: r= 0.99, and Levine mAge: r=
0.98). We proceeded with the quantile-normalized
methylation data for all subsequent analyses given its
use in previous studies of mAge acceleration11,34.
Upon performing a Cox regression analyses for mor-
tality in SCZ, we did not detect a significant association
(all p > 0.005) between the three mAge acceleration esti-
mators and mortality in SCZ in any of the following
comparisons: SCZ-died vs. SCZ alive (Table 3), and SCZ-
died vs. controls-died; SCZ-died vs. controls alive (Sup-
plementary Table S3). The equivalent analysis in controls
was also performed, with similar effect sizes seen in pre-
vious studies10, albeit non-significant due to the smaller
sample sizes (Supplementary Table S3). Findings were
similar for unadjusted and adjusted hazard ratios across
all comparisons, and none reached statistical significance.
Additionally, a stepwise bidirectional Cox regression
model was used to examine the individual effects of white
blood cell counts, age at sampling, sex, and smoking
scores on the three mAge acceleration estimators and
mortality in SCZ, which revealed that no factors remained
independently significant (all p > 0.005, Supplementary
Table S4).
The least square means from an adjusted linear model
of Hannum mAge in all individuals (N= 378) revealed no
significant effects of case-control status (p= 0.284) or
mortality (p= 0.925, Supplementary Table S5). Similar
findings were observed for a linear model using mAge
acceleration (i.e., residuals), removing the interaction
term from both linear models, and repeating these
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Fig. 1 Plot of predicted Hannum methylation age (mAge) against age at sampling, by status: a SCZ-died, b SCZ-alive, c Control-died, d
Control-alive. Correlation between age at sampling and Hannum mAge across all samples was 0.85. r= Pearson correlation coefficient, black line=
linear model, gray region= 95% confidence intervals
Table 3 Cox regression analyses of mAge acceleration
versus mortality in schizophrenia cases
mAge
estimator
Unadjusted hazard ratio
(95%CI)
Adjusted hazard ratio
(95%CI)a
Hannum 1.04 (0.99–1.10), p= 0.11 1.07 (1.01–1.13), p= 0.02
Horvath 1.02 (0.98–1.07), p= 0.41 1.03 (0.98–1.08), p= 0.24
Levine 1.02 (0.98–1.05), p= 0.45 1.00 (0.96–1.05), p= 0.84
aAdjusted for white blood cell counts, age, sex, smoking score, and methylation
batch. The sample for this analysis is n= 126 SCZ died vs. n= 63 SCZ alive
Kowalec et al. Translational Psychiatry           (2019) 9:157 Page 5 of 8
analyses using the Horvath and Levine mAge estimators
(all p ≥ 0.1). We tested the association between mAge
acceleration and known risk factors for mortality using
linear regression (Supplementary Table S6) and there
were no factors significantly associated with mAge
acceleration in SCZ.
Sensitivity analyses
We removed 37 individuals who had died within the
first two years of sampling (nscz= 20; ncontrols= 17) and
repeated the Cox regression analyses, with no change to
the pattern of results; no mAge acceleration estimator was
significantly associated with mortality in SCZ (all p >
0.005, Supplementary Table S7). As a second sensitivity
analyses, we removed 73 individuals who were >65 years
at the time of sampling from the controls-died group
(Supplementary Table S8). A significant result was iden-
tified in the unadjusted analyses for the Hannum esti-
mator (hazard ratio= 1.06, 95% confidence interval=
1.02–1.11, p= 0.004), however, there was less certainty
regarding this effect, upon adjusting for confounders (p=
0.009). The remaining findings from this sensitivity ana-
lyses were again in line with our primary findings, in
addition to complementary analyses performed in con-
trols only (p ≥ 0.2). We then removed 130 individuals
(SCZ-died: n= 43, SCZ-alive: n= 7, control-died: n= 74,
control-alive: n= 6) with any treatment contacts for a
serious cancer that may affect mAge acceleration (Table
4). These sensitivity analyses revealed a significant finding
for the Hannum mAge acceleration and mortality in SCZ
(hazard ratio= 1.13, 95% confidence interval= 1.04–1.22,
p= 0.005), although the 95% confidence intervals were
broader in this smaller cohort, compared to the primary
analyses. Finally, a sensitivity analyses was performed
whereby we removed 147 individuals (SCZ-died: n= 43,
control-died: n= 104) who were >65 years at the time of
sampling and had any treatment contact for a serious
cancer. The results for the mAge acceleration and SCZ
and mortality were as previous (p-values adjusted for
white blood cell counts, age, sex, smoking score, and
methylation batch: Hannum [p= 0.016], Horvath [p=
0.441], Levine [p= 0.754]).
Power calculation
Given our null results, it is important to determine the
statistical power to detect a difference. For the key ana-
lyses of SCZ died vs. SCZ alive, we performed a power
calculation using the R package powerSurvEpi. We had
>80% power to detect the expected effect size for mAge
acceleration and mortality in SCZ (p= 0.005, 189 sub-
jects, proportion died= 0.66, expected hazard ratio=
1.1718). The expected hazard ratio is derived from a pre-
vious study reporting mAge acceleration was associated
with mortality in cancer (hazard ratio= 1.17, 95%CI= Ta
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1.07–1.28)18. We hypothesized that this effect size was
more appropriate than the smaller effects reported by the
all-cause mortality studies of non-diseased individuals
(e.g., Chen et al.10).
Discussion
We conducted a well-powered case-control study
within a Swedish study of SCZ and controls17, finding the
evidence was too weak to support our pre-specified pri-
mary hypothesis that mAge acceleration is associated with
mortality in SCZ. mAge acceleration has been previously
associated with all-cause mortality, including in a large
meta-analysis of 13,089 individuals (2734 deaths; p ≤ 8.2 ×
10−9)10, with similar findings in smaller cohorts5,7,35.
However, these previous studies used population-based
cohorts of individuals with no specific disease and thus, it
is possible that the underlying mechanism of mAge
acceleration as a predictor of mortality differs in SCZ.
Investigations of the association between mAge accel-
eration and mortality specifically in psychiatric disorders
are currently lacking. Thus, to the best of our knowledge,
this study represents the first of its kind in relation to
mortality and SCZ.
Although the evidence was not strong enough to sug-
gest that mAge acceleration is associated with mortality in
SCZ, there remains the possibility of this association in
tissues outside the blood, or smaller effects, particularly
within patient subsets. For example, mAge acceleration
has been noted in individuals with Down’s syndrome
using brain and blood samples but not buccal epithe-
lium36. However, SCZ studies not specifically investigat-
ing mortality that employed different brain tissues and
blood found no evidence of mAge acceleration12–16. More
specifically, these mAge acceleration studies in SCZ
involved samples from the superior temporal gyrus (N=
22 SCZ, 22 controls)12 and frontal cortex (N= 199 SCZ,
241 controls)13 and found no association between mAge
acceleration and SCZ. The lack of association was repli-
cated in samples from dorsolateral prefrontal cortex (N=
195 SCZ, 232 controls; p= 0.60) and blood (N= 592 SCZ,
707 controls; p ≥ 0.1)16. There remains the possibility that
since 25% of SCZ cases died in this study from cardio-
vascular disease, samples of heart tissue could point to a
possible association between mAge acceleration and
mortality in SCZ and presents an interesting avenue for
future investigations.
We assessed the effects of multiple confounders on the
association of mAge acceleration and mortality in SCZ.
Owing to our study design, the age at sampling was
similar for all subject groups, apart from the control-died
group, who were older. However, there was evidence of
residual age confounding by the change in the hazard
ratio following the removal of older individuals (>65 years
at sampling) from the control-died group during the
sensitivity analyses. We also assessed the effects of acute
illness on mAge acceleration by removing individuals who
died within the first two years of sampling and the find-
ings did not change. Removing individuals with a lifetime
treatment contact for a serious cancer revealed a sig-
nificant finding for the Hannum estimator, although this
finding requires follow up in a larger cohort of individuals
with SCZ and without cancer. This finding highlights the
importance of having age-matched controls and excluding
individuals with pre-existing cancer in investigating the
association of mAge acceleration and mortality.
Our study had multiple strengths. We selected all sub-
jects to be of a similar age at sampling to reduce con-
founding and we performed sensitivity analyses to exclude
the possibility that individuals who were older at the time
of sampling had influenced the results. The ability to
ascertain the actual cause of death is a strength as it meant
we were able to exclude subjects who died from external
causes, as these would be less likely to be affected by
mAge acceleration. Rather than employing logistic
regression to assess the association between mAge
acceleration and mortality in SCZ, our primary analyses
involved a Cox proportional hazards regression model,
which was able to assess simultaneously the effect of
mAge acceleration on mortality and varying lengths of
follow-up between subjects. Further, we employed mul-
tiple mAge estimators, including Hannum, which was
developed for the same sample type used here (adult
blood samples)6. A limitation of our study included an
inability to assess the influence of additional confounders
on the association of mAge acceleration and mortality,
such as the use of valproic acid37, or patient character-
istics, such as body mass index38.
In conclusion, in a sample of SCZ cases and controls
with considerable follow-up, we found no evidence to
suggest that mAge acceleration was associated with
mortality. However, future studies in this area may con-
sider investigating mAge acceleration in SCZ patient
subsets without cancer or including longitudinal mea-
surements of blood in SCZ to determine whether mAge
acceleration changes over time39. Additionally, the advent
of the single cell technologies may reveal a relationship
between mAge acceleration and SCZ mortality by eluci-
dating the individual cell type contributing to aging, tissue
repair, or tissue rejuvenation in SCZ40.
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